DXC020

DXC020 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Hangzhou DAC Biotech for the treatment of solid tumors. It specifically targets CD54 (also known as intercellular adhesion molecule 1 or ICAM-1), a cell surface glycoprotein often overexpressed in various malignancies. The drug is designed to utilize a monoclonal antibody to deliver a cytotoxic payload directly to CD54-expressing cancer cells, thereby inducing cell death while potentially reducing systemic toxicity. As of current reports, the specific payload and linker technology remain proprietary, and the candidate is undergoing preclinical evaluation.